TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04978168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Intervention
Description: Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Specialists (PSS)
Description: Participants randomized to PSS will meet with a PSS for 6 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
Study: NCT05405452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Anesthesia Device by Blaine Labs
Description: Device which vibrates on top of skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauers Ethyl Chloride 100% Topical Spray
Description: Sterile ethyl chloride spray
Study: NCT04310423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to endotoxin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Bolus dose of 0.8 ng/kg
Study: NCT05837494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Ozone and corticosteroids
Description: patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular PRGF Method
Description: Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors \[PRGF\] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration.
Study: NCT05130242

Intervention type: PROCEDURE
Intervention: Cement-augmented Pedicle Screws (CPS)
Description: Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine

Intervention type: PROCEDURE
Intervention: Hybrid Construct (HC)
Description: Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
Study: NCT04690868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-213-A
Description: 1 tablet administered before the breakfast during 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-213-A
Description: 1 tablet administered before the breakfast during 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2131
Description: 1 tablet administered before the breakfast during 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2131
Description: 1 tablet administered before the breakfast during 5 days
Study: NCT05359497

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Multiscan sequences baseline
Description: Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRCP+ analysis baseline
Description: Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan analysis baseline
Description: Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI liver with MRCP
Description: An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Multiscan sequences follow-up
Description: Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRCP+ analysis follow up
Description: Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan analysis follow up
Description: Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
Study: NCT05236478

Intervention type: OTHER
Intervention: CoviMouv' program
Description: * An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~* A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~* Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~* The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~* Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months.

Intervention type: OTHER
Intervention: Control
Description: The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
Study: NCT05077657

Intervention type: DEVICE
Intervention: Early Bird® Bleed Monitoring System
Description: The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.

Intervention type: DEVICE
Intervention: Impella®
Description: Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
Study: NCT04076748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMONO
Description: In the control group, patients will receive EMONO then IV morphine as soon as possible.
Study: NCT06244446

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study
Study: NCT05401760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A :combined phacoaspiration and angle surgery
Description: * Partial thickness scleral flap to access the canal of schlemm.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B : phacoaspiration only
Description: * 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.
Study: NCT05681182

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: CardiaMend with the Addition of Amiodarone
Description: The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
Study: NCT06431152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC sEV
Description: Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC sEV
Description: Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC sEV
Description: Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose
Study: NCT05311891

Intervention type: DIAGNOSTIC_TEST
Intervention: RT PCR
Description: Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons

Intervention type: DIAGNOSTIC_TEST
Intervention: RT PCR
Description: Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Study: NCT05859503

Intervention type: OTHER
Intervention: Closure Strategy with Perclose-Proglide system
Description: Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure

Intervention type: OTHER
Intervention: Closure Strategy with figure-of-8
Description: Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
Study: NCT04513223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
Study: NCT05957380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803
Description: All participants are administered one tablet per day for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2803-R
Description: All participants are administered one tablet per day for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of DA-2803
Description: All participants are administered one tablet per day for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of DA-2803-R
Description: All participants are administered one tablet per day for 48 weeks
Study: NCT05318417

Intervention type: DEVICE
Group type: OTHER
Intervention: The Cochlear™ Nucleus® Cochlear Implant (CI) System
Description: The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®.
Study: NCT06375551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimizing Responses with Collaborative Assessments-Automated (ORCA-A)
Description: Participants will receive automated facilitation in the ORCA platform. This will entail prompts for group discussion based on group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Participants will have the option of using these prompts to discuss ORCA results in group decision discussions.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimizing Responses with Collaborative Assessments-Live (ORCA-L)
Description: A facilitator will guide group decision discussions using group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Facilitation will be either in-person or virtual, but occur live as in during real-time.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation.
Study: NCT06217510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Brace
Description: Participants will be fitted with the Test Brace and will wear the brace for 30 minutes.
Study: NCT06373029

Intervention type: OTHER
Intervention: Ultrasound examination
Description: The investigators made ultrasound examinations to the participants to test whether the model could improve their diagnostic accuracy
Study: NCT05126433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
Study: NCT04654065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004
Description: One time dose of IN-C004 taken orally.
Study: NCT06424626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+Axitinib
Description: Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112+Axitinib
Description: Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
Study: NCT05884151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelets rich plasma
Description: Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
Study: NCT05917197

Intervention type: OTHER
Intervention: survey based information
Description: Only survey based information collected
Study: NCT05960253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group Block
Description: 1st group to be applied PENG block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumber Erector Spinae Plane Block
Description: 2nd group to be applied Lumber ESP block
Study: NCT06085001

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumella finger prick blood test
Description: Finger prick blood test
Study: NCT06530446

Intervention type: OTHER
Intervention: one group. observational study
Description: observational study of this group
Study: NCT05132907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDT-301
Description: HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDT-301
Description: HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDT-301
Description: HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
Study: NCT04857476

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound scan
Description: Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years
Study: NCT04449250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmethylphenidate
Description: Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmethylphenidate
Description: Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
Study: NCT05327296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Inhaled isoflurane administered by Sedaconda ACD-S

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous infusion of propofol
Study: NCT05096585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed bedtime sleep restriction
Description: bedtime 2 hr later than their normal bedtime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed bedtime sleep restriction
Description: bedtime 2 hr later than their normal bedtime

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed bedtime sleep restriction
Description: bedtime 2 hr later than their normal bedtime

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early wake sleep restriction
Description: wake time 2 hr earlier than their normal wake time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early wake sleep restriction
Description: wake time 2 hr earlier than their normal wake time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Early wake sleep restriction
Description: wake time 2 hr earlier than their normal wake time
Study: NCT05954520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympan
Description: Participants will wear a prototype hearing aid (called the Tympan)
Study: NCT06241768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-CRC Web app
Description: Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-CRC Web app
Description: Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-CRC Web app
Description: Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-CRC Web app
Description: Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening
Study: NCT06526039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a novel short regimen
Description: An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.
Study: NCT05488015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Description: GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle habits
Description: No change in lifestyle habits during the 8-week trial.
Study: NCT04291820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous induction and desflurane anaesthesia maintenance
Description: Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane
Description: Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels